

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")  
Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India  
Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in  
Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/- THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
<b>Weighted Average EPS</b>	<b>9.01</b>	<b>6</b>

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
<b>Weighted Average EPS</b>	<b>9.04</b>	<b>6</b>

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
<b>Weighted Average</b>	<b>37.21</b>	<b>6</b>

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
<b>Weighted Average</b>	<b>37.36</b>	<b>6</b>

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
<b>Weighted Average</b>	<b>27.49</b>
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
<b>Weighted Average</b>	<b>27.54</b>
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.20%	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

- Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.
- The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditor's Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

#### Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three year period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 25094768MB06UT2282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%)	23.83%	29.54%	5.74%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(7)</sup>	-596.08	1824.60	646.80
PAT <sup>(8)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(9)</sup>	0.41	0.49	0.03
EPS <sup>(10)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")  
Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India  
Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in  
Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/- THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
Weighted Average EPS	9.01	6

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
Weighted Average EPS	9.04	6

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
Weighted Average	37.21	6

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
Weighted Average	37.36	6

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
Weighted Average	27.49
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
Weighted Average	27.54
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-23	31-Mar-25				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

• Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.

• The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three year period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 250947658M06BUT2282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%)	23.83%	23.54%	5.74%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(7)</sup>	-596.08	1824.60	646.80
PAT <sup>(8)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(9)</sup>	0.41	0.49	0.03
EPS <sup>(10)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")

Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India

Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in

Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/-

THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
<b>Weighted Average EPS</b>	<b>9.01</b>	<b>6</b>

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
<b>Weighted Average EPS</b>	<b>9.04</b>	<b>6</b>

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
<b>Weighted Average</b>	<b>37.21</b>	<b>6</b>

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
<b>Weighted Average</b>	<b>37.36</b>	<b>6</b>

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
<b>Weighted Average</b>	<b>27.49</b>
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
<b>Weighted Average</b>	<b>27.54</b>
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-23	31-Mar-25				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

• Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.

• The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditor's Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three year period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 25094768MB08UT2282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%)	23.83%	29.54%	5.74%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(7)</sup>	-596.08	1824.60	646.80
PAT <sup>(8)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(9)</sup>	0.41	0.49	0.03
EPS <sup>(10)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")  
Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India  
Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in  
Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/- THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
Weighted Average EPS	9.01	6

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
Weighted Average EPS	9.04	6

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
Weighted Average	37.21	6

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
Weighted Average	37.36	6

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
Weighted Average	27.49
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
Weighted Average	27.54
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

- Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.
- The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 25094768MB08UT2282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%)	23.83%	29.54%	5.74%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(7)</sup>	-596.08	1824.60	646.80
PAT <sup>(8)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(9)</sup>	0.41	0.49	0.03
EPS <sup>(10)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")  
Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India  
Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in  
Company Secretary and Compliance Officer: MD. Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/- THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
Weighted Average EPS	9.01	6

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
Weighted Average EPS	9.04	6

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
Weighted Average	37.21	6

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
Weighted Average	37.36	6

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
Weighted Average	27.49
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
Weighted Average	27.54
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-23	31-Mar-25				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.20%	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

- Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.
- The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

#### Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three year period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co. Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 250947658M0802282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025			Financial Year ended March 31, 2024			Financial Year ended March 31, 2023		
	Revenue	EBITDA	PAT	Revenue	EBITDA	PAT	Revenue	EBITDA	PAT
Revenue from operations <sup>(1)</sup>	8323.92	2847.40	1595.54	7850.36	2234.02	1233.82	23012.08	4133.34	2351.55
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.21%	1.96	34.49%	28.46%	1.63	34.9%	28.46%	1.01
EBITDA <sup>(3)</sup>	2847.40	27.46%	1.96	2234.02	28.46%	1.63	4133.34	28.46%	1.01
EBITDA (%) Margin <sup>(4)</sup>	34.21%	27.46%	1.96	28.46%	28.46%	1.63	17.96%	28.46%	1.01
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	28.83%	1.96	28.46%	28.54%	1.63	14.78%	28.54%	1.01
ROCE (%)	23.10%	29.54%	5.74%	16.45%	35.20%	15.61%	15.29%	21.38%	18.62%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17
Operating Cash flow <sup>(7)</sup>	-596.08			1824.60			646.80		
PAT <sup>(8)</sup>	1591.26			1233.82			57.32		
ROE/ RONW <sup>(9)</sup>	0.41			0.49			0.03		
EPS <sup>(10)</sup> (after considering bonus)	11.79			9.14			0.42		

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")  
Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India  
Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in  
Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/- THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
Weighted Average EPS	9.01	6

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
Weighted Average EPS	9.04	6

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
Weighted Average	37.21	6

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
Weighted Average	37.36	6

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
Weighted Average	27.49
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
Weighted Average	27.54
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended		Financial year ended		Financial year ended		Financial year ended					
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-23	31-Mar-25				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
Vijaya Diagnostic Centre Ltd	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
Metropolis Healthcare Ltd	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
EBITDA	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
EBITDA Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Profit after tax	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
PAT Margin (%)	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Return on Equity (ROE) (%)	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Debt to Equity Ratio	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Interest Coverage Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Return on Capital Employed (ROCE) (%)	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76
Current Ratio	* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.											
Net Capital Turnover Ratio	Notes:											
	• Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.											
	• The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.											
	For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditor's Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.											
	Key financial and operational performance indicators ("KPIs")											
	The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 250947658M06BUT2282.											
	The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.											
	Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.											
	Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.											
	KPI Indicators (Standalone)											
	(Amount in ₹ lakhs, except EPS, % and ratios)											
	Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023								
	Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12								
	Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%								
	EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62								
	EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%								
	EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%								
	ROCE (%) <sup>(6)</sup>	23.83%	23.54%	5.74%								
	Current Ratio <sup>(7)</sup>	1.96	1.63	1.01								
	Operating Cash flow <sup>(8)</sup>	-596.08	1824.60	646.80								
	PAT <sup>(9)</sup>	1591.26	1233.82	57.32								
	ROE/ RONW <sup>(10)</sup>	0.41	0.49	0.03								
	EPS <sup>(11)</sup> (after considering bonus)	11.79	9.14	0.42								

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")

Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India

Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in

Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/-

THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
<b>Weighted Average EPS</b>	<b>9.01</b>	<b>6</b>

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
<b>Weighted Average EPS</b>	<b>9.04</b>	<b>6</b>

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
<b>Weighted Average</b>	<b>37.21</b>	<b>6</b>

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
<b>Weighted Average</b>	<b>37.36</b>	<b>6</b>

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
<b>Weighted Average</b>	<b>27.49</b>
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
<b>Weighted Average</b>	<b>27.54</b>
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-23	31-Mar-25				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

- Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.
- The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 25094768MB06UT2282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%)	23.83%	29.54%	5.74%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(7)</sup>	-596.08	1824.60	646.80
PAT <sup>(8)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(9)</sup>	0.41	0.49	0.03
EPS <sup>(10)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")

Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India

Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in

Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/-

THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
<b>Weighted Average EPS</b>	<b>9.01</b>	<b>6</b>

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
<b>Weighted Average EPS</b>	<b>9.04</b>	<b>6</b>

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
<b>Weighted Average</b>	<b>37.21</b>	<b>6</b>

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
<b>Weighted Average</b>	<b>37.36</b>	<b>6</b>

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
<b>Weighted Average</b>	<b>27.49</b>
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
<b>Weighted Average</b>	<b>27.54</b>
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-23	31-Mar-25				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

• Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.

• The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditor's Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three year period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 250947658M0602282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%) <sup>(6)</sup>	23.83%	29.54%	5.74%
Current Ratio <sup>(7)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(8)</sup>	-596.08	1824.60	646.80
PAT <sup>(9)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(10)</sup>	0.41	0.49	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")

Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India  
Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in  
Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/-

THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
Weighted Average EPS	9.01	6

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
Weighted Average EPS	9.04	6

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
Weighted Average	37.21	6

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
Weighted Average	37.36	6

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
Weighted Average	27.49
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
Weighted Average	27.54
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-23	31-Mar-25				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

- Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.
- The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

#### Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 250947658M0602282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%)	23.83%	29.54%	5.74%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(7)</sup>	-596.08	1824.60	646.80
PAT <sup>(8)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(9)</sup>	0.41	0.49	0.03
EPS <sup>(10)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")  
Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India  
Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in  
Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/- THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
Weighted Average EPS	9.01	6

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
Weighted Average EPS	9.04	6

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
Weighted Average	37.21	6

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
Weighted Average	37.36	6

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
Weighted Average	27.49
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
Weighted Average	27.54
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.20%	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

- Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.
- The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 25094768MB06UT2282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%)	23.83%	29.54%	5.74%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(7)</sup>	-596.08	1824.60	646.80
PAT <sup>(8)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(9)</sup>	0.41	0.49	0.03
EPS <sup>(10)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")

Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India  
Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in  
Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/- THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

##### 1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
Weighted Average EPS	9.01	6

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
Weighted Average EPS	9.04	6

##### 2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

##### 3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
Weighted Average	37.21	6

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
Weighted Average	37.36	6

##### 4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
Weighted Average	27.49
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
Weighted Average	27.54
Offer Price	142

##### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24				
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

#### Notes:

- Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.
- The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditor's Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

#### Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 25094768MB06UT2282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%)	23.83%	29.54%	5.74%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(7)</sup>	-596.08	1824.60	646.80
PAT <sup>(8)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(9)</sup>	0.41	0.49	0.03
EPS <sup>(10)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")  
Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India  
Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in  
Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/- THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
Weighted Average EPS	9.01	6

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
Weighted Average EPS	9.04	6

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
Weighted Average	37.21	6

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
Weighted Average	37.36	6

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
Weighted Average	27.49
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
Weighted Average	27.54
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended		Financial year ended		Financial year ended		Financial year ended					
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-23	31-Mar-25				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
Vijaya Diagnostic Centre Ltd	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
Metropolis Healthcare Ltd	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
EBITDA	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
EBITDA Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Profit after tax	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
PAT Margin (%)	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Return on Equity (ROE) (%)	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Debt to Equity Ratio	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Interest Coverage Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Return on Capital Employed (ROCE) (%)	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76
Current Ratio	* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.											
Net Capital Turnover Ratio	Notes:											
	• Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.											
	• The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.											
	For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditor's Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.											
	Key financial and operational performance indicators ("KPIs")											
	The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three year period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 25094768MB06UT2282.											
	The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.											
	Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.											
	Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.											
	KPI Indicators (Standalone)											
	(Amount in ₹ lakhs, except EPS, % and ratios)											
	Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023								
	Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12								
	Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%								
	EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62								
	EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%								
	EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%								
	ROCE (%) <sup>(6)</sup>	23.83%	23.54%	5.74%								
	Current Ratio <sup>(7)</sup>	1.96	1.63	1.01								
	Operating Cash flow <sup>(8)</sup>	-596.08	1824.60	646.80								
	PAT <sup>(9)</sup>	1591.26	1233.82	57.32								
	ROE/ RONW <sup>(10)</sup>	0.41	0.49	0.03								
	EPS <sup>(11)</sup> (after considering bonus)	11.79	9.14	0.42								

Continued to next page...

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# STAR IMAGING AND PATH LAB LIMITED

(FORMERLY KNOWN AS "STAR IMAGING AND PATH LAB PRIVATE LIMITED")

Corporate Identity Number: U85110DL2004PLC126679

Our Company was originally incorporated as a private limited company under the Companies Act, 1956 in the name and style of "Star Imaging & Path Lab Private Limited" bearing Corporate Identification Number U85110DL2004PTC126679 dated May 31, 2004 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting held on April 12, 2024 and consequently the name of our Company was changed from "Star Imaging & Path Lab Private Limited" to "Star Imaging and Path Lab Limited" vide a fresh certificate of incorporation dated September 17, 2024 issued by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies of Central Processing Centre bearing Corporate Identification Number U85110DL2004PLC126679. For further details please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 192 of this Prospectus dated August 12, 2025 ("Prospectus").

Registered Office: 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India

Tel: +91 9990019189; Fax: N.A.; Website: www.starimaging.in; E-mail: cs@starimaging.in

Company Secretary and Compliance Officer: MD, Shadab Khan

## OUR PROMOTERS: MR. PAWAN GUPTA AND MS. CHHAYA GUPTA

### INITIAL PUBLIC OFFER OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED (BSE) IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018

The company operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi (B2C, B2B & B2G model), Uttar Pradesh (B2G model), and Nasik (B2G Model) regions of India. The Company started its journey from 1978 as proprietorship under the name of Janta X-Ray Clinic and were providing X-ray and basic pathology tests using manual methods. Over the years, they have upgraded their services, equipment, and diagnostic technologies to incorporate the latest advancements in medical science, ensuring the care and improved patient outcomes. This vision led to the establishment of Star Imaging & Path Lab Private Limited in 2004, as Private Limited entity, with a vision to offer pathology, radiology, Cardiology, and Neurology services under one roof. As part of our expansion, we acquired the businesses of Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care in 2011. For further details, please refer chapter titled "Business Overview" beginning on Page no. 139 of this Prospectus.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF 48,92,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF STAR IMAGING AND PATH LAB LIMITED ("STAR" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 6946.64 LAKHS ("THE OFFER"), COMPRISING A FRESH OFFER OF 39,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING UP TO ₹ 5566.40 LAKHS BY OUR COMPANY ("FRESH OFFER") AND AN OFFER FOR SALE OF 9,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE ("OFFERED SHARES") AGGREGATING UP TO ₹ 1380.24 LAKHS BY MR. PAWAN GUPTA (SELLING SHAREHOLDER). OUT OF THE OFFER, 4,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 681.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO (THE "MARKET MAKER RESERVATION PORTION"). THIS ISSUE INCLUDES A RESERVATION OF 52,000 EQUITY SHARES AGGREGATING TO ₹ 73.84 LAKHS (CONSTITUTING 0.299% OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION AND ELIGIBLE EMPLOYEES i.e. NET OFFER OF 43,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 142/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 132/- PER EQUITY SHARE AGGREGATING TO ₹ 6191.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE 28.083% AND 25.029% RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

## THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 142/-

THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: ₹ 142 PER EQUITY SHARE THE ISSUE PRICE IS 14.20 TIMES OF THE FACE VALUE

### BID/ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, AUGUST 07, 2025

BID/ OFFER OPENED ON: FRIDAY, AUGUST 08, 2025

BID/ OFFER CLOSED ON: TUESDAY, AUGUST 12, 2025

### RISKS TO INVESTORS

SUMMARY DESCRIPTION OF KEY RISK FACTORS BASED ON MATERIALITY

- Our Company, Promoter and Directors are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.
- There have been instances in the past where we have not made regulatory filing of Consolidated Financials of our Company with RoC
- Our Company has reported certain negative cash flows from its operating activity, investing activity and financing activity, details of which are given below
- Our Company has not fulfilled its CSR obligation u/s 135 of the Companies Act, 2013 for the F.Y. 2021-22 to F.Y. 2023-24. Such non-compliance/ default may attract penalties on the Company and its Directors.
- Form-2 for Return of Allotment filed with the Registrar of Companies for the period April 28, 2011 is not traceable

#### DETAILS OF SUITABLE RATIOS:

1) Basic and Diluted Earnings per Share (EPS) as per Accounting Standard 20.

On the basis of Restated Standalone financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.79	3
2023-24	9.14	2
2022-23	0.42	1
<b>Weighted Average EPS</b>	<b>9.01</b>	<b>6</b>

On the basis of Restated Consolidated financials:

Financial Year	EPS (Basic & Diluted)	Weight
2024-25	11.80	3
2023-24	9.20	2
2022-23	0.43	1
<b>Weighted Average EPS</b>	<b>9.04</b>	<b>6</b>

2) Price to Earnings (P/E) ratio in relation to Issue Price of ₹ 142/- per Equity Share of face value ₹ 10/- each fully paid up.

On the basis of Financials:

Particulars	P/E Ratio at floor price	P/E Ratio at cap price
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	11.45	12.04
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2023-24	14.77	15.54
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2022-23	321.43	338.10
P/E ratio based on the Weighted Average EPS, as restated	14.98	15.76

3) Return on Net Worth (RONW)

On the basis of Restated Standalone Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.63	3
2023-24	49.16	2
2022-23	3.07	1
<b>Weighted Average</b>	<b>37.21</b>	<b>6</b>

On the basis of Restated Consolidated Financials:

Financial Year	Return on Net Worth (%)	Weight
2024-25	40.65	3
2023-24	49.53	2
2022-23	3.13	1
<b>Weighted Average</b>	<b>37.36</b>	<b>6</b>

4) Net Asset Value per Equity Share

On the basis of Restated Standalone financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.86
2023-24	23.16
2022-23	14.02
<b>Weighted Average</b>	<b>27.49</b>
Offer Price	142

On the basis of Restated Consolidated financials:

Particulars	Net Asset Value (NAV) in Rs.
2024-25	34.93
2023-24	23.22
2022-23	14.03
<b>Weighted Average</b>	<b>27.54</b>
Offer Price	142

#### 5) Comparison with industry peers

Particulars	Financial year ended											
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-23	31-Mar-25				
Star Imaging and Path Lab Limited	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Chandan Healthcare Ltd												
Vijaya Diagnostic Centre Ltd												
Metropolis Healthcare Ltd												
Revenue From operations	8350.01	7850.36	5837.12	23012.08	17659.01	13688.94	68139.01	54780.53	45922.27	133120.30	120770.88	114821.02
Total Income	8378.74	7969.25	5852.07	23217.22	17795.86	13702.92	69070.96	56862.33	47337.34	134631.60	121682.58	116343.48
EBITDA	2860.15	2234.02	580.62	4133.34	2610.27	927.41	27321.59	21884.89	18202.73	27321.59	28257.55	28829.59
EBITDA Margin (%)	34.25%	28.46%	9.95%	17.96%	14.78%	6.77%	40.1%	39.95%	39.64%	40.09%	23.40%	25.11%
Profit after tax	1595.54	1233.82	57.32	2351.55	1635.5	358.63	14379.35	11963.71	8520.7	14551.29	12845.56	14339.4
PAT Margin (%)	19.10%	15.72%	0.98%	10.22%	9.26%	2.62%	21.10%	21.84%	18.55%	10.93%	10.64%	12.49%
Return on Equity (ROE) (%)	33.84%	49.16%	3.07%	19.18%	47.50%	13.11%	18.07%	19.91%	16.82%	10.93%	12.33%	15.30%
Debt to Equity Ratio	0.69	0.98	1.40	0.39	1.02	0.78	0.40	0.39	0.45	.01	0	0.08
Interest Coverage Ratio	9.57	8.35	1.5	8.01	10.01	4.01	8.26	9.12	8.69	11.27	12.54	10.76
Return on Capital Employed (ROCE) (%)	23.10%	29.54%	5.74%	16.45%	35.205	15.61%	15.29%	21.38%	18.62%	12.20%	18.23%	19.38%
Current Ratio	1.96	1.63	1.01	1.94	1.05	0.95	1.89	2.90	4.17	1.17	1.28	1.14
Net Capital Turnover Ratio	1.77	7.60	11.22	1.88	709.91	-54.65	0.86	3.15	2.22	1	22.42	17.76

\* Information in relation to listed peers mentioned above are on a standalone basis and is sourced from their respective audited financial results and/or annual report.

Notes:

• Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.

• The figures for Star Imaging and Path Lab Limited are based on the restated consolidated results for the year ended March 31, 2025.

For further details, see the section titled Risk Factors beginning on page 29 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditor's Report and Financial Information of Our Company beginning on page 230 of the Prospectus for a more informed view.

Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated 19th March, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three year period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s. BHS & Co, Chartered Accountants by their certificate dated 25th July, 2025 having UDIN: 25094768MB06UT2282.

The KPIs of our Company have been disclosed in the sections "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" starting on page numbers 139 and 295, respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" beginning on page number 02.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilization of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Offer Section, whichever is later or for such other duration as may be required under the SEBI (ICDR) Regulations, 2018.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

Particulars	Financial Year ended March 31, 2025		
	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8323.92	7850.36	5837.12
Growth in Revenue from Operations <sup>(2)</sup>	6.03%	34.49%	-15.33%
EBITDA <sup>(3)</sup>	2847.40	2234.02	580.62
EBITDA (%) Margin <sup>(4)</sup>	34.21%	28.46%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.46%	284.76%	-60.43%
ROCE (%)	23.83%	29.54%	5.74%
Current Ratio <sup>(6)</sup>	1.96	1.63	1.01
Operating Cash flow <sup>(7)</sup>	-596.08	1824.60	646.80
PAT <sup>(8)</sup>	1591.26	1233.82	57.32
ROE/ RONW <sup>(9)</sup>	0.41	0.49	0.03
EPS <sup>(10)</sup> (after considering bonus)	11.79	9.14	0.42

Continued to next page...

Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (% Margin) <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025.\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,05,118 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	6,37,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>	

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	
<b>Total</b>		<b>2,29,33,000</b>	<b>100.00</b>		

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**

**Disclaimer:** Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/issuances/>, and is available on the website of the BRLM at [www.shareindia.com](http://www.shareindia.com). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be sold or issued within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,54,200 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% to Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
<b>TOTAL</b>	<b>1,731</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>			<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors - Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63 : 161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5 : 13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1 : 3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2 : 7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2 : 5	6,000
<b>Total</b>	<b>189</b>	<b>189</b>	<b>100.00</b>	<b>6,27,000</b>	<b>100.00</b>			<b>21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 10 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors - Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5,072.4 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133 : 232	39,900
2	9,000	12	4.69	1,08,000	4.82	3,000	7 : 12	21,000
3	10,000	5	1.95	50,000	2.23	3,000	3 : 5	9,000
4	12,000	1	0.39	12,000	0.54	3,000	0 : 1	0
5	14,000	1	0.39	14,000	0.62	3,000	0 : 1	0
6	15,000	2	0.78	30,000	1.34	3,000	1 : 2	3,000
7	30,000	1	0.39	30,000	1.34	3,000	0 : 1	0
8	71,000	2	0.78	1,42,000	6.33	3,000	1 : 2	3,000
<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>2,24,20,000</b>	<b>100.00</b>				<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	2,000	2	40.00	4,000	30.77	2,000	1 : 1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1 : 1	9,000
<b>TOTAL</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>				<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.7 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1 : 1	4,80,000
<b>TOTAL</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>				<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-Syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
Tel: +91 40 6716 2222/18003094001 Fax: N/A  
Email: [sip1.ip@kfintech.com](mailto:sip1.ip@kfintech.com)  
Website: [www.kfintech.com](http://www.kfintech.com)  
SEBI Registration No INR000000221

On behalf of Board of Directors  
**FOR, STAR IMAGING AND PATH LAB LIMITED**  
Sd/-  
**Mr. Shadab Khan**  
Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
CIN: L32209KA1988PLC039313  
Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
Tel:+91 80 2839 6102 / 2839 6291  
E-mail: [support@adcock.com](mailto:support@adcock.com) Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS - 100 DAYS CAMPAIGN - 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [enward.rts@kfintech.com](mailto:enward.rts@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
Place: Bangalore R.Ganesh  
Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
Regd. Office:1, Karpur Road, Prayagraj-211001  
CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

**Dear Members,**  
Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 09th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.triveniglassltd.com](http://www.triveniglassltd.com) and on the website of NSDL at <https://www.evoting.nsdl.com>. The remote e-voting facility shall begin on Saturday, 06th September, 2025 at 9:00 AM and end on Monday, 08th September, 2025 at 5:00 PM. A person whose name appears in the register of members/beneficial owners as on the cut-off date i.e. 02nd September 2025 only shall be entitled to avail the facility of remote e-voting as well as voting at meeting. Any person, who becomes member of the company after dispatch of the notice of the meeting and holding shares as on the cut-off date i.e. 02nd September 2025 may obtain the facility of remote e-voting by sending request at <https://www.evoting.nsdl.com>. The detailed procedure for obtaining user id and password is also provided in the notice of meeting which is available on Company's website and NSDL's website. If the member id already registered with NSDL for e-voting then he can use existing user id and password for casting the vote through remote e-voting. The members who cast their

Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (% Margin) <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,05,118 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	3,63,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>	

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	
<b>Total</b>		<b>2,29,33,000</b>	<b>100.00</b>		

Place: New Delhi

Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
 Disclaimer: Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/issuances/>, and is available on the website of the BRLM at [www.shareindia.in](http://www.shareindia.in). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
 The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be sold or issued within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
<b>TOTAL</b>	<b>2,000</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>			<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors- Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63 : 161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5 : 13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1 : 3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2 : 7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2 : 5	6,000
<b>Total</b>	<b>2,000</b>	<b>189</b>	<b>100.00</b>	<b>6,27,000</b>	<b>100.00</b>	<b>3,000</b>	<b>2 : 10</b>	<b>2,21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 100 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors- Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5,072.4 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to total	No. of Equity shares Allotted per Bidder	Ratio	Total No. of shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133 : 232	39,90,000
2	9,000	12	4.69	1,08,000	4.82	3,000	7 : 12	21,000
3	10,000	5	1.95	50,000	2.23	3,000	3 : 5	9,000
4	12,000	1	0.39	12,000	0.54	3,000	0 : 1	0
5	14,000	1	0.39	14,000	0.62	3,000	0 : 1	0
6	15,000	2	0.78	30,000	1.34	3,000	1 : 2	3,000
7	30,000	1	0.39	30,000	1.34	3,000	0 : 1	0
8	71,000	2	0.78	1,42,000	6.33	3,000	1 : 2	3,000
						1,000	2 : 3	6,000
						1,000	1 : 147	1,000
<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>2,24,20,000</b>	<b>100.00</b>				<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	2,000	2	40.00	4,000	30.77	2,000	1 : 1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1 : 1	9,000
<b>TOTAL</b>	<b>5,000</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>			<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.7 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1 : 1	4,80,000
<b>TOTAL</b>	<b>4,80,000</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>			<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-Syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
 Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
 Contact Person: Mr. Murali Krishna  
 Tel: +91 40 6716 2222/18003094001 Fax: N/A  
 Email: sip1.ip@kfintech.com  
 Website: [www.kfintech.com](http://www.kfintech.com)  
 SEBI Registration No INR000000221

On behalf of Board of Directors  
**FOR, STAR IMAGING AND PATH LAB LIMITED**  
 Sd/-  
**Mr. Shadab Khan**  
 Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
 CIN: L32209KA1988PLC039313  
 Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
 Tel:+91 80 2839 6102 / 2839 6291  
 E-mail: support@adcock.com Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS 100 DAYS CAMPAIGN – 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [enward.rs@kfintech.com](mailto:enward.rs@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
 Place: Bangalore R.Ganesh  
 Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
 Regd. Office:1, Karpur Road, Prayagraj-211001  
 CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

Dear Members,  
 Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 09th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing

Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (%) Margin <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIBs Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,05,118 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	6,37,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>	

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	
<b>Total</b>		<b>2,29,33,000</b>	<b>100.00</b>		

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
Disclaimer: Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/publicdiscuss>, and is available on the website of the BRLM at [www.shareindia.in](http://www.shareindia.in). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be sold or issued within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
<b>TOTAL</b>	<b>2,000</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>			<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors- Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity Shares allotted to applicants	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63 : 161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5 : 13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1 : 3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2 : 7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2 : 5	6,000
<b>Total</b>	<b>2,000</b>	<b>189</b>	<b>100.00</b>	<b>6,27,000</b>	<b>100.00</b>	<b>3,000</b>	<b>2 : 10</b>	<b>2,21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 100 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors- Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5,672.4 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied in each category	% to total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133 : 232	39,90,000
2	9,000	12	4.69	1,08,00,000	4.82	3,000	7 : 12	21,000
3	10,000	5	1.95	50,00,000	2.23	3,000	3 : 5	9,000
4	12,000	1	0.39	12,00,000	0.54	3,000	0 : 1	0
5	14,000	1	0.39	14,00,000	0.62	3,000	0 : 1	0
6	15,000	2	0.78	30,00,000	1.34	3,000	1 : 2	3,000
7	30,000	1	0.39	30,00,000	1.34	3,000	0 : 1	0
8	71,000	2	0.78	14,20,00,000	6.33	3,000	1 : 2	3,000
						1,000	2 : 3	6,000
						1,000	1 : 147	1,000
<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>22,20,000</b>	<b>100.00</b>				<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	2,000	2	40.00	4,000	30.77	2,000	1 : 1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1 : 1	9,000
<b>TOTAL</b>	<b>5,000</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>			<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.7 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1 : 1	4,80,000
<b>TOTAL</b>	<b>4,80,000</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>			<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-Syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
Tel: +91 40 6716 2222/18003094001 Fax: N/A  
Email: sip1.ip@kfintech.com  
Website: [www.kfintech.com](http://www.kfintech.com)  
SEBI Registration No INR000000221

On behalf of Board of Directors  
**FOR, STAR IMAGING AND PATH LAB LIMITED**  
Sd/-  
**Dr. Shadab Khan**  
Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
CIN: L32209KA1988PLC039313  
Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
Tel:+91 80 2839 6102 / 2839 6291  
E-mail: support@adcock.com Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS - 100 DAYS CAMPAIGN - 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [enward.rs@kfintech.com](mailto:enward.rs@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
Place: Bangalore R.Ganesh  
Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
Regd. Office:1, Karpur Road, Prayagraj-211001  
CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

Dear Members,  
Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 09th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.triveniglassltd](http://www.triveniglassltd.com)

Continued from previous page...

- Notes:**  
 (1) Revenue from operations is the total revenue generated by our Company.  
 (2) Growth in Revenue in percentage, Year on Year  
 (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income  
 (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations  
 (5) EBITDA Growth Rate Year on Year in Percentage  
 (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt  
 (7) Current Ratio: Current Asset over Current Liabilities  
 (8) Operating Cash Flow: Net cash inflow from operating activities.  
 (9) PAT is mentioned as PAT for the period  
 (10) ROE/RNW is calculated as PAT divided by average shareholders' equity  
 (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (% Margin) <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**  
 (1) Revenue from operations is the total revenue generated by our Company.  
 (2) Growth in Revenue in percentage, Year on Year  
 (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income  
 (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations  
 (5) EBITDA Growth Rate Year on Year in Percentage  
 (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt  
 (7) Current Ratio: Current Asset over Current Liabilities  
 (8) Operating Cash Flow: Net cash inflow from operating activities.  
 (9) PAT is mentioned as PAT for the period  
 (10) ROE/RNW is calculated as PAT divided by average shareholders' equity  
 (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,05,118 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	36,37,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
	<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	-
	<b>Total</b>	<b>2,29,33,000</b>	<b>100.00</b>	-	-

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
 Disclaimer: Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/issuances/>, and is available on the website of the BRLM at [www.shareindia.in](http://www.shareindia.in). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
 The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be sold or issued within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
	<b>TOTAL</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>	-	-	<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors - Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63 : 161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5 : 13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1 : 3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2 : 7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2 : 5	6,000
	<b>Total</b>	<b>189</b>	<b>100.00</b>	<b>6,27,000</b>	<b>100.00</b>	<b>3,000</b>	<b>2 : 10</b>	<b>2,21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 100 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors - Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5.0724 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied in each category	% to total	No. of Equity shares Allotted per Bidder	Ratio	Total No. of shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133 : 232	39,90,000
2	9,000	12	4.69	1,08,00,000	4.82	3,000	7 : 12	21,000
3	10,000	5	1.95	50,00,000	2.23	3,000	3 : 5	9,000
4	12,000	1	0.39	12,00,000	0.54	3,000	0 : 1	0
5	14,000	1	0.39	14,00,000	0.62	3,000	0 : 1	0
6	15,000	2	0.78	30,00,000	1.34	3,000	1 : 2	3,000
7	30,000	1	0.39	30,00,000	1.34	3,000	0 : 1	0
8	71,000	2	0.78	14,20,00,000	6.33	3,000	1 : 2	3,000
	<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>22,20,00,000</b>	<b>100.00</b>	<b>3,000</b>	<b>1 : 147</b>	<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	2,000	2	40.00	4,000	30.77	2,000	1 : 1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1 : 1	9,000
	<b>TOTAL</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>	<b>3,000</b>	<b>1 : 1</b>	<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.75 times of QIB Portion. The total number of Equity Shares Allotted in the QIB Category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1 : 1	4,80,000
	<b>TOTAL</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>	-	-	<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-Syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
 Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
 Contact Person: Mr. Murali Krishna  
 Tel: +91 40 6716 2222/18003094001 Fax: N/A  
 Email: sipil ipo@kfintech.com  
 Website: [www.kfintech.com](http://www.kfintech.com)  
 SEBI Registration No INR000000221

On behalf of Board of Directors  
**FOR, STAR IMAGING AND PATH LAB LIMITED**  
 Sd/-  
**Mr. Shadab Khan**  
 Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
 CIN: L32209KA1988PLC009313  
 Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
 Tel:+91 80 2839 6102 / 2839 6291  
 E-mail: support@adcock.com Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS 100 DAYS CAMPAIGN - 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [eiwardr.fs@kfintech.com](mailto:eiwardr.fs@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
 Place: Bangalore R.Ganesh  
 Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
 Regd. Office:1, Karpur Road, Prayagraj-211001  
 CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

Dear Members,  
 Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 09th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.evoting.nsdl.com](https://www.evoting.nsdl.com) and on the website of NSDL at <https://www.evoting.nsdl.com>. The remote e-voting facility shall begin on Saturday, 06th September, 2025 at 9:00 AM and end on Monday, 08th September, 2025 at 5:00 PM. A person whose name appears in the register of members/beneficial owners as on the cut-off date i

Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (% Margin) <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIBs"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,0518 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	3,63,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>	

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	95,000	0.42	95,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	
<b>Total</b>		<b>2,29,33,000</b>	<b>100.00</b>		

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
Disclaimer: Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/epublicusss>, and is available on the website of the BRLM at [www.shareindia.in](http://www.shareindia.in). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be sold or issued within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
<b>TOTAL</b>	<b>2,000</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>			<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors - Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity shares allotted per applicants	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63 : 161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5 : 13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1 : 3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2 : 7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2 : 5	6,000
<b>Total</b>	<b>2,000</b>	<b>189</b>	<b>100.00</b>	<b>6,27,000</b>	<b>100.00</b>			<b>21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 100 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors - Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5,072.4 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to total	No. of Equity shares Allotted per Bidder	Ratio	Total No. of shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133 : 232	35,90,000
2	9,000	12	4.69	1,08,000	4.82	3,000	7 : 12	21,000
3	10,000	5	1.95	50,000	2.23	3,000	3 : 5	9,000
4	12,000	1	0.39	12,000	0.54	3,000	0 : 1	0
5	14,000	1	0.39	14,000	0.62	3,000	0 : 1	0
6	15,000	2	0.78	30,000	1.34	3,000	1 : 2	3,000
7	30,000	1	0.39	30,000	1.34	3,000	0 : 1	0
8	71,000	2	0.78	1,42,000	6.33	3,000	1 : 2	3,000
						1,000	2 : 3	6,000
						1,000	1 : 147	10,000
<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>2,24,20,000</b>	<b>100.00</b>				<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	2,000	2	40.00	4,000	30.77	2,000	1 : 1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1 : 1	9,000
<b>TOTAL</b>	<b>5,000</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>			<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.7 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1 : 1	4,80,000
<b>TOTAL</b>	<b>4,80,000</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>			<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
Contact Person: Mr. Murali Krishna  
Tel: +91 40 6716 2222/18003094001 Fax: N/A  
Email: [sipil ipo@kfintech.com](mailto:sipil ipo@kfintech.com)  
Website: [www.kfintech.com](http://www.kfintech.com)  
SEBI Registration No INR000000221

On behalf of Board of Directors  
FOR, STAR IMAGING AND PATH LAB LIMITED  
Sd/-  
Md. Shadab Khan  
Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
CIN: L32209KA1888PLC03913  
Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
Tel:+91 80 2839 6102 / 2839 6291  
E-mail: [support@adcock.com](mailto:support@adcock.com) Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS - 100 DAYS CAMPAIGN - 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [enward.rs@kfintech.com](mailto:enward.rs@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
Place: Bangalore R.Ganesh  
Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
Regd. Office:1, Karpur Road, Prayagraj-211001  
CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

Dear Members,  
Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 09th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting intral containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.evoting.nsdl.com](https://www.evoting.nsdl.com) and on the website of NSDL at <https://www.evoting.nsdl.com>. The remote e-voting facility shall begin on Saturday, 06th September, 202

Continued from previous page...

- Notes:**  
 (1) Revenue from operations is the total revenue generated by our Company.  
 (2) Growth in Revenue in percentage, Year on Year  
 (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income  
 (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations  
 (5) EBITDA Growth Rate Year on Year in Percentage  
 (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt  
 (7) Current Ratio: Current Asset over Current Liabilities  
 (8) Operating Cash Flow: Net cash inflow from operating activities.  
 (9) PAT is mentioned as PAT for the period  
 (10) ROE/RNW is calculated as PAT divided by average shareholders' equity  
 (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (% Margin) <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**  
 (1) Revenue from operations is the total revenue generated by our Company.  
 (2) Growth in Revenue in percentage, Year on Year  
 (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income  
 (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations  
 (5) EBITDA Growth Rate Year on Year in Percentage  
 (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt  
 (7) Current Ratio: Current Asset over Current Liabilities  
 (8) Operating Cash Flow: Net cash inflow from operating activities.  
 (9) PAT is mentioned as PAT for the period  
 (10) ROE/RNW is calculated as PAT divided by average shareholders' equity  
 (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025.\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,05,18 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	6,33,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>	

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	
<b>Total</b>		<b>2,29,33,000</b>	<b>100.00</b>		

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
 Disclaimer: Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/publicdiscuss>, and is available on the website of the BRLM at [www.shareindia.in](http://www.shareindia.in). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
 The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
<b>TOTAL</b>	<b>1,731</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>			<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors-Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63:161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5:13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1:3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2:7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2:5	6,000
<b>Total</b>	<b>189</b>	<b>189</b>	<b>100.00</b>	<b>62,70,000</b>	<b>100.00</b>			<b>21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 10 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors-Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5,072.4 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied in each category	% to total	No. of Equity shares Allotted per Bidder	Ratio	Total No. of shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133:232	39,90,000
2	9,000	12	4.69	1,08,000	4.82	3,000	7:12	21,000
3	10,000	5	1.95	50,000	2.23	3,000	3:5	9,000
4	12,000	1	0.39	12,000	0.54	3,000	0:1	0
5	14,000	1	0.39	14,000	0.62	3,000	0:1	0
6	15,000	2	0.78	30,000	1.34	3,000	1:2	3,000
7	30,000	1	0.39	30,000	1.34	3,000	0:1	0
8	71,000	2	0.78	1,42,000	6.33	3,000	1:2	3,000
<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>224,20,000</b>	<b>100.00</b>				<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	2,000	2	40.00	4,000	30.77	2,000	1:1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1:1	9,000
<b>TOTAL</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>				<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.7 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1:1	4,80,000
<b>TOTAL</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>				<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
 Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
 Contact Person: Mr. Murali Krishna  
 Tel: +91 40 6716 2222/18003094001 Fax: N/A  
 Email: sipil ipo@kfintech.com  
 Website: www.kfintech.com  
 SEBI Registration No INR000000221

On behalf of Board of Directors  
**FOR, STAR IMAGING AND PATH LAB LIMITED**  
 Sd/-  
**Mr. Shabab Khan**  
 Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
 CIN: L32209KA1988PLC009313  
 Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
 Tel:+91 80 2839 6102 / 2839 6291  
 E-mail: support@adcock.com Website: www.adcock.com

**NOTICE TO SHAREHOLDERS 100 DAYS CAMPAIGN – 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: einward.rts@kfintech.com; Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
 Place: Bangalore R.Ganesh  
 Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
 Regd. Office:1, Karpur Road, Prayagraj-211001  
 CIN: L26101UP 1971PLC003491 Email: akd@triveniglassltd.com  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

**Dear Members,**  
 Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 9th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting intranet containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.evoting.nsdl.com](https://www.evoting.nsdl.com) and on the website of NSDL at <https://www.evoting.nsdl.com>. The remote e-voting facility shall begin on Saturday, 06th September, 2025 at 9:00 AM and end on Monday, 08th September, 2025 at 5:00 PM. A person whose name appears in the register of members/beneficial owners as on the cut-off date i.e. 02nd September 2025 only shall be entitled to avail the facility of remote e-voting as well as voting at meeting. Any person, who becomes member of the company after dispatch of the notice of the meeting and holding shares as on the cut-off date i.e. 02nd September 2025 may obtain the facility of remote e-voting by sending request at <https://www.evoting.nsdl.com>. The detailed procedure for obtaining user id and password is also provided in the notice of meeting which is available on Company's website and NSDL's website. If the member id already registered with NSDL for e-voting then he can use existing user id and password for casting the vote through remote e-voting. The members who cast their vote by remote e-voting may attend the meeting but shall not be entitled to cast their vote again. Further, the facility for voting through

Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (% Margin) <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,05,118 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	6,33,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
	<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	-
	<b>Total</b>	<b>2,29,33,000</b>	<b>100.00</b>	-	-

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
**Disclaimer:** Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/issuances>, and is available on the website of the BRLM at [www.shareindia.in](http://www.shareindia.in). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
 The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be sold or issued within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% to Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
	<b>TOTAL</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>	-	-	<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors - Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63 : 161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5 : 13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1 : 3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2 : 7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2 : 5	6,000
	<b>Total</b>	<b>189</b>	<b>100.00</b>	<b>6,27,000</b>	<b>100.00</b>	<b>3,000</b>	<b>2 : 10</b>	<b>21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 100 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors - Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5,072.4 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to total	No. of Equity shares Allotted per Bidder	Ratio	Total No. of shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133 : 232	39,90,000
2	9,000	12	4.69	1,08,000	4.82	3,000	7 : 12	21,000
3	10,000	5	1.95	50,000	2.23	3,000	3 : 5	9,000
4	12,000	1	0.39	12,000	0.54	3,000	0 : 1	0
5	14,000	1	0.39	14,000	0.62	3,000	0 : 1	0
6	15,000	2	0.78	30,000	1.34	3,000	1 : 2	3,000
7	30,000	1	0.39	30,000	1.34	3,000	0 : 1	0
8	71,000	2	0.78	1,42,000	6.33	3,000	1 : 2	3,000
	<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>22,20,000</b>	<b>100.00</b>	<b>3,000</b>	<b>1 : 147</b>	<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	2,000	2	40.00	4,000	30.77	2,000	1 : 1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1 : 1	9,000
	<b>TOTAL</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>	<b>3,000</b>	<b>1 : 1</b>	<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.7 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1 : 1	4,80,000
	<b>TOTAL</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>	-	-	<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-Syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.  
 Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
 Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
 Contact Person: Mr. Murali Krishna  
 Tel: +91 40 6716 2222/18003094001 Fax: N/A  
 Email: sipil ipo@kfintech.com  
 Website: [www.kfintech.com](http://www.kfintech.com)  
 SEBI Registration No INR000000221

On behalf of Board of Directors  
**FOR, STAR IMAGING AND PATH LAB LIMITED**  
 Sd/-  
**Mr. Shadab Khan**  
 Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
 CIN: L32209KA1988PLC009313  
 Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
 Tel:+91 80 2839 6102 / 2839 6291  
 E-mail: support@adcock.com Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS 100 DAYS CAMPAIGN – 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [eiwardr.fs@kfintech.com](mailto:eiwardr.fs@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
 Place: Bangalore R.Ganesh  
 Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
 Regd. Office:1, Karpur Road, Prayagraj-211001  
 CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

Dear Members,  
 Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 09th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.evoting.nsdl.com](https://www.evoting.nsdl.com) and on the website of NSDL at <https://www.evoting.nsdl.com>. The remote e-voting facility shall begin on Saturday, 06th September, 2025 at 9:00 AM and end on Monday, 08th September, 2025 at 5:00 PM. A person whose name appears in the register of members/beneficial owners as on the cut-off date i.e. 02nd September 2025 only shall be entitled to avail the facility of remote e-voting as well as

Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (% Margin) <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025\*

\* Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,05,118 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	6,33,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>	

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	
<b>Total</b>		<b>2,29,33,000</b>	<b>100.00</b>		

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
**Disclaimer:** Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/issuances/>, and is available on the website of the BRLM at [www.shareindia.in](http://www.shareindia.in). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
 The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be sold or issued within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,54,200 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
<b>TOTAL</b>	<b>1,731</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>			<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors - Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% of Total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63 : 161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5 : 13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1 : 3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2 : 7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2 : 5	6,000
<b>Total</b>	<b>189</b>	<b>189</b>	<b>100.00</b>	<b>6,27,000</b>	<b>100.00</b>			<b>21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 10 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors - Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5,674.2 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied in each category	% to total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133 : 232	39,90,000
2	9,000	12	4.69	1,08,000	4.82	3,000	7 : 12	21,000
3	10,000	5	1.95	50,000	2.23	3,000	3 : 5	9,000
4	12,000	1	0.39	12,000	0.54	3,000	0 : 1	0
5	14,000	1	0.39	14,000	0.62	3,000	0 : 1	0
6	15,000	2	0.78	30,000	1.34	3,000	1 : 2	3,000
7	30,000	1	0.39	30,000	1.34	3,000	0 : 1	0
8	71,000	2	0.78	1,42,000	6.33	3,000	1 : 2	3,000
<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>2,24,20,000</b>	<b>100.00</b>				<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	2,000	2	40.00	4,000	30.77	2,000	1 : 1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1 : 1	9,000
<b>TOTAL</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>				<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.7 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1 : 1	4,80,000
<b>TOTAL</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>				<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-Syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
 Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
 Contact Person: Mr. Murali Krishna  
 Tel: +91 40 6716 2222/18003094001 Fax: N/A  
 Email: sipil ipo@kfintech.com  
 Website: [www.kfintech.com](http://www.kfintech.com)  
 SEBI Registration No INR000000221

On behalf of Board of Directors  
**FOR, STAR IMAGING AND PATH LAB LIMITED**  
 Sd/-  
**Mr. Shadab Khan**  
 Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
 CIN: L32209KA1988PLC009313  
 Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
 Tel:+91 80 2839 6102 / 2839 6291  
 E-mail: support@adcock.com Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS 100 DAYS CAMPAIGN - 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [eiwardr.fs@kfintech.com](mailto:eiwardr.fs@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
 Place: Bangalore R.Ganesh  
 Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
 Regd. Office:1, Karpur Road, Prayagraj-211001  
 CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

**Dear Members,**  
 Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 09th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.evoting.nsdl.com](https://www.evoting.nsdl.com) and on the website of NSDL at <https://www.evoting.nsdl.com>. The remote e-voting facility shall begin on Saturday, 06th September, 2025 at 9:00 AM and end on Monday, 08th September, 2025 at 5:00 PM. A person whose name appears in the register of members/beneficial owners as on the cut-off date i.e. 02nd September 2025 only shall be entitled to avail the facility of remote e-voting as well as voting at meeting. Any person, who becomes member of the company after dispatch of the notice of the meeting and holding shares as on the cut-off date i.e. 02nd September 2025 may obtain the facility of remote e-voting by sending request at <https://www.evoting.nsdl.com>. The detailed procedure for obtaining user id and password is also provided in the notice of meeting which is available on Company's website and NSDL's website. If the member id already registered with NSDL for e-voting then he can use existing user id and password for casting the vote through remote e-voting. The members who cast their vote by remote e-voting may attend the meeting but shall not be entitled to cast their vote again.

Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation - Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RONW is calculated as Profit before tax + Depreciation - Interest Expenses - Other Income
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares
- KPI Indicators (Consolidated)**
- | Particulars                                      | Financial Year ended March 31, 2025 | Financial Year ended March 31, 2024 | Financial Year ended March 31, 2023 |
|--|-------------------------------------|-------------------------------------|-------------------------------------|
| Revenue from operations <sup>(1)</sup>           | 8350.01                             | 7878.41                             | 5853.23                             |
| Growth in Revenue from Operations <sup>(2)</sup> | 5.99%                               | 34.60%                              | -15.28%                             |
| EBITDA <sup>(3)</sup>                            | 2857.24                             | 2245.66                             | 582.12                              |
| EBITDA (% Margin) <sup>(4)</sup>                 | 34.22%                              | 28.50%                              | 9.95%                               |
| EBITDA Growth Period on Period <sup>(5)</sup>    | 27.23%                              | 285.77%                             | -60.34%                             |
| ROCE (%) <sup>(6)</sup>                          | 29.92%                              | 29.99%                              | 5.77%                               |
| Current Ratio <sup>(7)</sup>                     | 1.93                                | 1.63                                | 1.01                                |
| Operating Cash Flow <sup>(8)</sup>               | -602.65                             | 1833.88                             | 527.15                              |
| PAT <sup>(9)</sup>                               | 1595.54                             | 1245.38                             | 58.29                               |
| ROE/ RONW <sup>(10)</sup>                        | 0.41                                | 0.50                                | 0.03                                |
| EPS <sup>(11)</sup> (after considering bonus)    | 11.80                               | 9.20                                | 0.43                                |

**Notes:**

- (1) Revenue from operations is the total revenue generated by our Company.
- (2) Growth in Revenue in percentage, Year on Year
- (3) EBITDA is calculated as Profit before tax + Depreciation - Interest Expenses - Other Income
- (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
- (5) EBITDA Growth Rate Year on Year in Percentage
- (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
- (7) Current Ratio: Current Asset over Current Liabilities
- (8) Operating Cash Flow: Net cash inflow from operating activities.
- (9) PAT is mentioned as PAT for the period
- (10) ROE/RONW is calculated as Profit before tax + Depreciation - Interest Expenses - Other Income
- (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") and with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIBs", the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the L1 Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025.\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/- . Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/- .

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,0518 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	6,33,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹ 0.2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,64,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>	

**Final Demand**

A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
<b>CUTOFF</b>	<b>142</b>	<b>0.00</b>	<b>0.00</b>	<b>2,29,33,000</b>	
<b>Total</b>	<b>2,29,33,000</b>	<b>100.00</b>			

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**

**Disclaimer:** Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of regulatory approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bsesme.com/PublicIssues/>, and is available on the websites of the BRLM at [www.sharadha.com](http://www.sharadha.com). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issuances and sales are made. There will be no public offering in the United States.

**ADC India Communications Ltd.**  
CIN: L32209KA1988PLC009313  
Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
Tel: +91 80 2839 6102 / 2839 6291  
E-mail: [notice@adcock.com](mailto:notice@adcock.com) Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS  
100 DAYS CAMPAIGN - 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account mandates, Nominee registration and contact information (email, mobile number, postal address) or have any issues/queries related to unpaid/unclaimed dividends and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFin Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [enward.rts@kfin.tech](mailto:enward.rts@kfin.tech); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPA on August 31, 2025.

Shareholders are further note that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
Place: Bangalore R.Ganesh  
Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
Regd. Office: Kanpur Road, Prayagraj-211001  
CIN: L26101UP 1971PLC003491 Email: [acd@triveniglassltd.com](mailto:acd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

**Dear Members,**  
Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 9th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at <https://www.evoting.nsdl.com> and on the website of NSDL at <https://www.evotingindia.com>. The remote e-voting facility shall begin on Saturday, 06th September, 2025 at 9:00 AM and end on Monday, 08th September, 2025 at 5:00 PM. A person whose name appears in the register of members/beneficial owners as on the cut-off date i.e. 02nd September 2025 only shall be entitled to avail the facility of remote e-voting as well as voting at meeting. Any person, who becomes member of the company after dispatch of the notice of the meeting and holding shares as on the cut-off date i.e. 02nd September 2025, may obtain the User ID and Password by sending request at <https://www.evoting.nsdl.com>. The detailed procedure for obtaining user id and password is also provided in the notice of meeting which is available on Company's website and NSDL's website. If the member is already registered with NSDL for e-voting then he can use existing user id and password for casting the vote through remote e-voting. The members who cast their vote by remote e-voting may attend the meeting but shall not be entitled to cast their vote again. Further, the facility for voting through poll shall also be made available at the meeting for members who have not cast their vote by remote e-voting. In case any queries/grievances relating to voting by electronic means, the members/beneficial owners may contact the following: The following address: Mr. Pratik Datta, Assistant Manager, National Securities Depository Ltd, Crescent Tower, Unit 3E, 3rd Floor, 2nd A.J.C. Bose Road, Kolkata-700020 West Bengal, India. Contact No.: 033-45179844/022-48667000 Email: [pratik@nsdl.com](mailto:pratik@nsdl.com)

By Order of the Board For Triveni Glass Limited  
Tanushee Chatterjee  
Company Secretary  
Place: Prayagraj  
Date: 16.08.2025

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	No. of Applications Received	% to Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/allotted
1	2,000	1,731	100.00	34,82,000	100.00	2,000	49:110	15,42,000
<b>TOTAL</b>	<b>2,000</b>	<b>1,731</b>	<b>100.00</b>	<b>34,82,000</b>	<b>100.00</b>			<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors - Above Rs. 2 Lakhs and Upto Rs.10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares Applied in each category	% to Total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	3000	161	85.19	4,83,000	77.03	3,000	63:161	1,89,000
2	4000	13	6.88	52,000	8.29	3,000	5:13	15,000
3	5000	3	1.59	15,000	2.39	3,000	1:3	3,000
4	6000	7	3.70	42,000	6.70	3,000	2:7	6,000
5	7000	5	2.65	35,000	5.58	3,000	2:5	6,000
<b>TOTAL</b>	<b>20,000</b>	<b>189</b>	<b>100.00</b>	<b>62,000</b>	<b>100.00</b>	<b>1,000</b>	<b>2:10</b>	<b>2,21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allocated to All the 10 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2: 10

**3) Allotment to Non-Institutional Investors - Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 5,072.04 times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications received	% to Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	8000	232	90.63	1,85,600	82.78	3,000	133:232	39,900
2	9,000	12	4.69	1,08,000	4.82	3,000	7:12	21,000
3	10,000	5	1.95	50,000	2.23	3,000	3:5	9,000
4	12,000	1	0.39	12,000	0.54	3,000	0:1	0
5	14,000	1	0.39	14,000	0.62	3,000	0:1	0
6	15,000	2	0.78	30,000	1.34	3,000	1:2	3,000
7	30,000	0.59	0.39	30,000	1.34	3,000	0:1	0
8	71,000	2	0.78	142,000	6.33	3,000	1:2	3,000
<b>TOTAL</b>	<b>256</b>	<b>256</b>	<b>100.00</b>	<b>2,24,200</b>	<b>100.00</b>	<b>1,000</b>	<b>1:147</b>	<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2: 3

Please Note: 1 additional lot of 1000 Share shall be allotted to all the successful allottees from 12000, 14000 & 30000 in the ratio of 1: 147

Note: The Share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees - (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalised in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to Total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	2,000	2	40.00	4,000	30.77	2,000	1:1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1:1	9,000
<b>TOTAL</b>	<b>5</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>			<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has 14 successful applicants. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 subscribed Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalised in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to Total	No. of equity shares Allocation per Applicant	Ratio of allottees to applicants	Total No. of shares allocated /allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1:1	4,80,000
<b>TOTAL</b>	<b>4,80,000</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>			<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC/SI	AIF	FPI	Total
ALLLOTMENT	71,000	11,82,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCESBs have been dispatched/ mailed for unlocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (% Margin) <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,05,118 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	6,33,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹ 2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
	<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	-
	<b>Total</b>	<b>2,29,33,000</b>	<b>100.00</b>	-	-

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
Disclaimer: Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/ebid/issuance>, and is available on the website of the BRLM at [www.shareindia.in](http://www.shareindia.in). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be sold or issued within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% to Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
	<b>TOTAL</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>	-	-	<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors- Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per applicants	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63 : 161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5 : 13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1 : 3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2 : 7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2 : 5	6,000
	<b>Total</b>	<b>189</b>	<b>100.00</b>	<b>6,27,000</b>	<b>100.00</b>	<b>3,000</b>	<b>2 : 10</b>	<b>2,21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 10 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors- Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5.0724 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied in each category	% to total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133 : 232	39,90,000
2	9,000	12	4.69	1,08,00,000	4.82	3,000	7 : 12	21,000
3	10,000	5	1.95	50,00,000	2.23	3,000	3 : 5	9,000
4	12,000	1	0.39	12,00,000	0.54	3,000	0 : 1	0
5	14,000	1	0.39	14,00,000	0.62	3,000	0 : 1	0
6	15,000	2	0.78	30,00,000	1.34	3,000	1 : 2	3,000
7	30,000	1	0.39	30,00,000	1.34	3,000	0 : 1	0
8	71,000	2	0.78	14,20,00,000	6.33	3,000	1 : 2	3,000
	<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>22,20,00,000</b>	<b>100.00</b>	<b>3,000</b>	<b>1 : 147</b>	<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	2,000	2	40.00	4,000	30.77	2,000	1 : 1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1 : 1	9,000
	<b>TOTAL</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>	<b>3,000</b>	<b>1 : 1</b>	<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.75 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1 : 1	4,80,000
	<b>TOTAL</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>	-	-	<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-Syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
Contact Person: Mr. Murali Krishna  
Tel: +91 40 6716 2222/18003094001 Fax: N/A  
Email: [sip1.ip@kfintech.com](mailto:sip1.ip@kfintech.com)  
Website: [www.kfintech.com](http://www.kfintech.com)  
SEBI Registration No INFR000000221

On behalf of Board of Directors  
FOR, STAR IMAGING AND PATH LAB LIMITED  
Sd/-  
Md. Shadab Khan  
Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
CIN: L32209KA1988PLC03913  
Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
Tel:+91 80 2839 6102 / 2839 6291  
E-mail: [support@adcock.com](mailto:support@adcock.com) Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS 100 DAYS CAMPAIGN – 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [enward.rs@kfintech.com](mailto:enward.rs@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
Place: Bangalore R.Ganesh  
Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
Regd. Office:1, Karpur Road, Prayagraj-211001  
CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

**Dear Members,**  
Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 09th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.evoting.nsdl.com](https://www.evoting.nsdl.com) and on the website of NSDL at <https://www.evoting.nsdl.com>. The remote e-voting facility shall begin on Saturday, 06th September, 2025 at 9:00 AM and end on Monday, 08th September, 2025 at 5:00 PM. A person

Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (% Margin) <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIBs"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,0518 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	3,63,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
<b>Total</b>	<b>2,251</b>	<b>1,81,26,000</b>	<b>35,88,000</b>	<b>5.05</b>	<b>2,57,35,44,000</b>	

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	
<b>Total</b>		<b>2,29,33,000</b>	<b>100.00</b>		

Place: New Delhi  
Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
**Disclaimer:** Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/ebid/issuance>, and is available on the website of the BRLM at [www.sharadindia.com](http://www.sharadindia.com). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
 The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be sold or issued within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
<b>TOTAL</b>	<b>2,000</b>	<b>1,731</b>	<b>100.00</b>	<b>34,62,000</b>	<b>100.00</b>			<b>15,42,000</b>

**2) Allotment to Non-Institutional Investors - Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per applicants	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63 : 161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5 : 13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1 : 3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2 : 7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2 : 5	6,000
<b>Total</b>	<b>2,000</b>	<b>189</b>	<b>100.00</b>	<b>6,27,000</b>	<b>100.00</b>	<b>3,000</b>	<b>2 : 10</b>	<b>2,21,000</b>

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 10 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors - Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5.0724 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied in each category	% to total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133 : 232	39,90,000
2	9,000	12	4.69	1,08,00,000	4.82	3,000	7 : 12	21,000
3	10,000	5	1.95	50,00,000	2.23	3,000	3 : 5	9,000
4	12,000	1	0.39	12,00,000	0.54	3,000	0 : 1	0
5	14,000	1	0.39	14,00,000	0.62	3,000	0 : 1	0
6	15,000	2	0.78	30,00,000	1.34	3,000	1 : 2	3,000
7	30,000	1	0.39	30,00,000	1.34	3,000	0 : 1	0
8	71,000	2	0.78	14,20,00,000	6.33	3,000	1 : 2	3,000
<b>TOTAL</b>	<b>256</b>	<b>100.00</b>	<b>22,20,000</b>	<b>100.00</b>		<b>3,000</b>	<b>1 : 147</b>	<b>4,42,000</b>

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	2,000	2	40.00	4,000	30.77	2,000	1 : 1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1 : 1	9,000
<b>TOTAL</b>	<b>5,000</b>	<b>5</b>	<b>100.00</b>	<b>13,000</b>	<b>100.00</b>			<b>13,000</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.75 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity Shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1 : 1	4,80,000
<b>TOTAL</b>	<b>4,80,000</b>	<b>1</b>	<b>100.00</b>	<b>4,80,000</b>	<b>100.00</b>			<b>4,80,000</b>

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-Syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
 Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
 Tel: +91 40 6716 2222/18003094001 Fax: N/A  
 Email: [sip1.ip@kfintech.com](mailto:sip1.ip@kfintech.com)  
 Website: [www.kfintech.com](http://www.kfintech.com)  
 SEBI Registration No INR000000221

On behalf of Board of Directors  
**FOR, STAR IMAGING AND PATH LAB LIMITED**  
 Sd/-  
**Mr. Shabab Khan**  
 Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
 CIN: L32209KA1988PLC009313  
 Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
 Tel:+91 80 2839 6102 / 2839 6291  
 E-mail: [support@adcock.com](mailto:support@adcock.com) Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS - 100 DAYS CAMPAIGN - 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [enward.rts@kfintech.com](mailto:enward.rts@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
 Place: Bangalore R.Ganesh  
 Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
 Regd. Office:1, Karpur Road, Prayagraj-211001  
 CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

**Dear Members,**  
 Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 9th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.triveniglassltd.com](http://www.triveniglassltd.com) and on the website of NSDL at <https://www.evoting.nsdl.com>



Continued from previous page...

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

Particulars	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
Revenue from operations <sup>(1)</sup>	8350.01	7878.41	5853.72
Growth in Revenue from Operations <sup>(2)</sup>	5.99%	34.60%	-15.28%
EBITDA <sup>(3)</sup>	2857.24	2245.66	582.12
EBITDA (%) Margin <sup>(4)</sup>	34.22%	28.50%	9.95%
EBITDA Growth Period on Period <sup>(5)</sup>	27.23%	285.77%	-60.34%
ROCE (%) <sup>(6)</sup>	23.92%	29.69%	5.77%
Current Ratio <sup>(7)</sup>	1.97	1.83	1.01
Operating Cash flow <sup>(8)</sup>	-602.65	1833.88	527.15
PAT <sup>(9)</sup>	1595.54	1245.98	58.29
ROE/RNW <sup>(10)</sup>	0.41	0.50	0.03
EPS <sup>(11)</sup> (after considering bonus)	11.80	9.20	0.43

- Notes:**
- (1) Revenue from operations is the total revenue generated by our Company.
  - (2) Growth in Revenue in percentage, Year on Year
  - (3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
  - (4) EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
  - (5) EBITDA Growth Rate Year on Year in Percentage
  - (6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus debt
  - (7) Current Ratio: Current Asset over Current Liabilities
  - (8) Operating Cash Flow: Net cash inflow from operating activities.
  - (9) PAT is mentioned as PAT for the period
  - (10) ROE/RNW is calculated as PAT divided by average shareholders' equity
  - (11) EPS is mentioned as EPS for the period as adjusted with bonus shares

**PROPOSED LISTING: AUGUST 18, 2025\***

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 225 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page 384. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 18, 2025\*

\*Subject to the receipt of listing and trading approval from the BSE ("BSE SME").

**SUBSCRIPTION DETAILS**

The bidding for Anchor Investors opened and closed on August 07, 2025. The Company received a total of 11 Anchor Investor Application Forms from 11 Anchor Investors for 1,934,000 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 274,628,000/-. Out of the total 11 Anchor Investor Application Forms, Nil Anchor Investor Application Forms were received from Domestic Mutual Funds (applying through Nil Schemes) for Nil Equity Shares. A total of 1,304,000 Equity Shares were allocated under the Anchor Investor Portion at Rs 142/- per Equity Share (including a share premium of Rs 132.00 per Equity Share) aggregating to Rs. 185,168,000/-.

The Issue (excluding Anchor Investors Portion) received 2,251 Applications for 1,81,26,000 Equity Shares (before technical rejections) resulting in 5,0518 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

**Detail of the Applications Received:**

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of Times Subscribed	Amount (Rs.)
1	Individual Investors	1,783	35,67,000	15,28,000	2.33	50,61,66,000
2	Non-institutional Investors (above ₹1 million)	191	6,33,000	2,19,000	2.89	8,98,86,000
3	Non-institutional Investors (More than ₹2 million and upto ₹1 million)	256	22,42,000	4,38,000	5.12	31,83,84,000
4	Qualified Institutional Bidders (excluding Anchor Investors)	14	1,11,88,000	8,71,000	12.85	1,58,86,96,000
5	Employee	6	16,000	52,000	0.31	22,72,000
6	Market Maker	1	4,80,000	4,80,000	1.00	6,81,60,000
Total		2,251	1,81,26,000	35,88,000	5.05	2,57,35,44,000

**Final Demand**

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	135	96,000	0.42	96,000	0.42
2	136	14,000	0.06	1,10,000	0.48
3	137	8,000	0.03	1,18,000	0.51
4	138	12,000	0.05	1,30,000	0.57
5	139	4,000	0.02	1,34,000	0.58
6	140	23,000	0.10	1,57,000	0.68
7	141	16,000	0.07	1,73,000	0.75
8	142	2,27,60,000	99.25	2,29,33,000	100.00
	CUTOFF	-	0.00	2,29,33,000	
Total		2,29,33,000	100.00		

Place: New Delhi

Date: August 14, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF STAR IMAGING AND PATH LAB LIMITED.**  
 Disclaimer: Star Imaging and Path Lab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, NCT of Delhi and Haryana, on August 13, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE SME at <https://www.bseindia.com/ebidiscuss/>, and is available on the website of the BRLM at [www.shareindia.in](http://www.shareindia.in). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 29 of the Prospectus.  
 The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on July 31, 2025.

**1) Allotment to Individual Investors (After Rejections)**

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,245.1 Times. The total number of Equity Shares Allotted in this category is 1,542,000 Equity Shares to 771 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% to Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
1	2,000	1,731	100.00	34,62,000	100.00	2,000	49 : 110	15,42,000
TOTAL	2,000	1,731	100.00	34,62,000	100.00			15,42,000

**2) Allotment to Non-Institutional Investors- Above Rs. 2 Lakhs and Upto Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 2,837.1 Times. The total number of Equity Shares Allotted in this category is 2,21,000 Equity Shares to 73 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to Total	Total No. of Shares applied in each category	% to total	No. of Equity shares allotted per applicants	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	3,000	161	85.19	4,83,000	77.03	3,000	63:161	1,89,000
2	4,000	13	6.88	52,000	8.29	3,000	5:13	15,000
3	5,000	3	1.59	15,000	2.39	3,000	1:3	3,000
4	6,000	7	3.70	42,000	6.70	3,000	2:7	6,000
5	7,000	5	2.65	35,000	5.58	3,000	2:5	6,000
TOTAL	2,000	189	100.00	62,70,000	100.00	3,000	2:10	2,21,000

Please Note: 1) (One) lot of 1000 shares have been allotted to All the 10 Successful Allottees from Category 4000 to 7000 (except Category 3000) in the ratio of 2 : 10

**3) Allotment to Non-Institutional Investors- Above Rs. 10 Lakhs (After Rejections)**

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 5.0724 Times. The total number of Equity Shares Allotted in this category is 4,42,000 Equity Shares to 147 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to total	No. of Equity shares Allotted per Bidder	Ratio	Total No. of Shares Allotted
1	8,000	232	90.63	1,85,60,000	82.78	3,000	133:232	35,90,000
2	9,000	12	4.69	1,08,00,000	4.82	3,000	7:12	21,000
3	10,000	5	1.95	50,00,000	2.23	3,000	3:5	9,000
4	12,000	1	0.39	12,00,000	0.54	3,000	0:1	0
5	14,000	1	0.39	14,00,000	0.62	3,000	0:1	0
6	15,000	2	0.78	30,00,000	1.34	3,000	1:2	3,000
7	30,000	1	0.39	30,00,000	1.34	3,000	0:1	0
8	71,000	2	0.78	14,20,00,000	6.33	3,000	1:2	3,000
TOTAL	256	256	100.00	22,20,00,000	100.00	3,000	1:147	4,42,000

Please Note: 1) (One) lot of 3000 shares have been allocated to All the 3 Applicants in Categories 12000, 14000 & 30000 in the ratio of 2 : 3

Please Note: 1) additional lot of 1000 Share shall be allotted to all the successful allottees from the Categories in the ratio of 1 : 147

Note: The share allocated under the Nil portion has been revised post finalization of Basis of Allotment, deviating from the figures disclosed in the RHP filed with the ROC on August 1, 2025.

**4) Allotment to Employees (After Rejections)**

The Basis of Allotment to the Employees, who have Bid at cut-off Price or at or above the Issue Price of Rs. 142/- per Equity Share, was finalized in consultation with BSE Limited. The category has been subscribed to the extent of 0.25 Times. The total number of Equity Shares Allotted in this category is 13,000 Equity Shares to 5 successful applicants. The details of the Basis of Allotment of the said category is as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1	2,000	2	40.00	4,000	30.77	2,000	1:1	4,000
2	3,000	3	60.00	9,000	69.23	3,000	1:1	9,000
TOTAL	5	5	100.00	13,000	100.00			13,000

**5) Allotment to QIBs excluding Anchor Investors (After Rejections)**

Allotment to QIBs, who have bid at the Issue Price of Rs. 142/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE Limited. This category has been subscribed to the extent of 12,570.75 times of QIB Portion. The total number of Equity Shares Allotted in the QIB category is 8,90,000 Equity Shares, which were allotted to 14 successful Applicants.

Category	FFC/FII	Others	Total
QIB	1,34,000	7,56,000	8,90,000

**1) Allotment to Market Maker (After Rejections & Withdrawal):** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹142/- per Equity Shares or above, was finalized in consultation with BSE Limited. The category was subscribed 1.00 times i.e. for 4,80,000 Equity Shares the total number of shares allotted in this category is 4,80,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No. of Equity shares Allotted per Applicant	Ratio of allottees to applicants	Total No. of shares allocated/ allotted
1	4,80,000	1	100.00	4,80,000	100.00	4,80,000	1:1	4,80,000
TOTAL	4,80,000	1	100.00	4,80,000	100.00			4,80,000

**2) Allotment to Anchor Investors (After Rejections)**

The Company in consultation with the BRLM has allocated 13,04,000 Equity Shares to 11 Anchor Investors at the Anchor Investor issue price of Rs. 142/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	NBFC'S	AIF	FPI	Total
ALLOTMENT	71,000	11,62,000	71,000	13,04,000

The Board of Directors of our Company at its meeting held on August 13, 2025, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Return Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before August 13, 2025, and payment to non-Syndicate brokers have been issued on August 14, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before August 14, 2025, for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on August 18, 2025.  
 Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated August 13, 2025 ("Prospectus").

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFIN TECHNOLOGIES LIMITED at [www.kfintech.com](http://www.kfintech.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

**KFIN TECHNOLOGIES LIMITED**  
 Sales Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032.  
 Contact Person: Mr. Murali Krishna  
 Tel: +91 40 6716 2222/18003094001 Fax: N/A  
 Email: sipil ipo@kfintech.com  
 Website: [www.kfintech.com](http://www.kfintech.com)  
 SEBI Registration No INR000000221

On behalf of Board of Directors  
**FOR, STAR IMAGING AND PATH LAB LIMITED**  
 Sd/-  
**Mr. Shadab Khan**  
 Company Secretary & Compliance Officer

**ADC India Communications Ltd.**  
 CIN: L32209KA1988PLC039313  
 Regd. Off: No.10C, 2nd Phase, 1st Main, Peenya Industrial Area, Bangalore-560058  
 Tel:+91 80 2839 6102 / 2839 6291  
 E-mail: support@adcock.com Website: [www.adcock.com](http://www.adcock.com)

**NOTICE TO SHAREHOLDERS 100 DAYS CAMPAIGN – 'SAKSHAM NIVESHAK'**

Pursuant to Investor Education and Protection Fund Authority (IEPPFA), Ministry of Corporate Affairs (MCA) directive, the Company has initiated a 100 Day campaign "Saksham Niveshak" from July 28, 2025 to November 6, 2025 for the shareholders who dividend remain unpaid/unclaimed. This notice is being issued by the Company as part of the aforesaid campaign.

Shareholders who have not claimed their dividends for any of the financial years from 2017-18 to 2024-25 or have not updated their Know Your Customer (KYC) details including PAN, Bank Account details, Bank account numbers, Nominee registration and contact information (email, mobile number, postal address) or have any issues/questions related to unpaid/unclaimed dividend and shares may write to the Company's Registrar and Transfer Agent (RTA) i.e. KFIN Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Hyderabad-500032. Email: [eiwardr.fds@kfintech.com](mailto:eiwardr.fds@kfintech.com); Toll Free: No. 1800 409 4001.

Shareholders may note that as per the provisions of the Companies Act, 2013, the unpaid/unclaimed dividend for the financial year 2017-18 and corresponding shares are due for transfer to IEPPFA on August 31, 2025.

Shareholders are further notified that this campaign has been initiated specifically to reach out to the shareholders to update their KYC and nomination details. The shareholders are requested to update their KYC details and claim their unpaid/unclaimed dividend to prevent their shares being transferred to the IEPPFA.

Shareholders holding shares in dematerialised form are requested to update their KYC details with their respective Depository Participant (DP) and contact the Company's RTA to claim unpaid/unclaimed Dividend.

For ADC India Communications Ltd  
 Place: Bangalore R.Ganesh  
 Date : August 18, 2025 Company Secretary

**Triveni Glass Limited**  
 Regd. Office:1, Karpur Road, Prayagraj-211001  
 CIN: L26101UP 1971PLC003491 Email: [akd@triveniglassltd.com](mailto:akd@triveniglassltd.com)  
**NOTICE OF E-VOTING FOR ANNUAL GENERAL MEETING ON 09.09.2025**

Dear Members,  
 Notice is hereby given that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company is providing its members facility to exercise their right to vote on resolutions proposed to be passed in the Annual General Meeting of the company scheduled to be held on Tuesday, 09th September 2025 at 12:00 PM at Hotel Allahabad Regency at 16, Tashkent Marg, Prayagraj-211001. The members may cast their votes using an electronic voting system from a place other than the venue of the meeting (remote e-voting). The company has engaged the service of National Securities Depository Limited (NSDL) as the Agency to provide e-voting facility. The communication relating to e-voting inter alia containing user id and password along with a copy of the notice convening the meeting has been dispatched to members. This communication and the Notice of the meeting are available on website of the Company at [www.triveniglassltd.com](http://www.triveniglassltd.com) and on the website of NSDL at <https://www.evoting.nsdl.com>. The remote e-voting facility shall begin on Saturday, 06th September, 2025 at 9:00 AM and end on Monday, 08th September, 2025 at 5:00 PM. A person whose name appears in the register of members/beneficial owners as on the cut-off date i.e. 02nd September 2025 only shall be entitled to avail the facility of remote e-voting as well as voting at meeting. Any person, who becomes member of the company after dispatch of the notice of the meeting and holding shares as on the cut-off date i.e. 02nd September 2025 may obtain the facility of remote e-voting by sending request at <https://www.evoting.nsdl.com>. The detailed procedure for obtaining user id and password is also provided in the notice of meeting which is available on Company's website and NSDL's website. If the member id already registered with NSDL for e-voting then he can use